A Study of ALXN1830 in Healthy Adult Participants
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of Subcutaneous ALXN1830 in Healthy Participants
Sponsor: Alexion Pharmaceuticals, Inc.
Terminated
Sponsor decision to terminate program
Other terminated trials from Alexion Pharmaceuticals, Inc.
- Immunoglobulin A Nephropathy · Phase PHASE2 · Aug 2025
- Geographic Atrophy · Phase PHASE2 · Jan 2025
- IgAN · Phase PHASE2 · Dec 2024
- Neurofibromatosis Type 1 · Nov 2024
- Healthy · Phase PHASE1 · Aug 2024
More terminations from Alexion Pharmaceuticals, Inc.
Listed as NCT04730804, this PHASE1 trial focuses on Healthy and remains terminated or withdrawn. Sponsored by Alexion Pharmaceuticals, Inc., it has been updated 10 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Oct 2024 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2023 — Jul 2024 [monthly]
Terminated PHASE1
-
Apr 2023 — Dec 2023 [monthly]
Terminated PHASE1
▶ Show 5 earlier versions
-
Feb 2023 — Apr 2023 [monthly]
Terminated PHASE1
-
Mar 2022 — Feb 2023 [monthly]
Terminated PHASE1
Status: Suspended → Terminated
-
Dec 2021 — Mar 2022 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Sep 2021 — Dec 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Alexion Pharmaceuticals, Inc.
- Syneos Health
For direct contact, visit the study record on ClinicalTrials.gov .